Abstract: An anti-HGFR antibody fragment in combination with an extracellular portion of human HGFR for use in the treatment of a patient suffering from a tumor and/or metastasis, wherein: (i) the anti-HGFR antibody fragment has only one paratope able to bind to an epitope of the extracellular portion of human HGFR and has antagonist activity towards HGFR, (ii) the extracellular portion of human HGFR is capable of binding to HGF in a stable manner and contains at least one amino acid mutation at the epitope recognized by the anti-HGFR antibody fragment to prevent binding of the anti-HGFR antibody fragment thereto, and (iii) the anti-HGFR antibody fragment and the extracellular portion of human HGFR are suitable for administration to the patient are suitable for administration to the patient (a) in a protein form or (b) in a nucleic acid form.